VIATRIS INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
VIATRIS INC. (VTRS) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $2.03 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.03B.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.07B.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.34B.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.33B.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $2.03B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.07B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.34B 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.33B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.32B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $2.25B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $2.23B 10-K · filed 2025-02-27 |
| 2024-09-30 | $2.30B 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.26B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.25B 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.31B 10-K · filed 2024-02-28 |
| 2023-09-30 | $2.22B 10-Q · filed 2023-11-08 |
| 2023-06-30 | $2.27B 10-Q · filed 2023-08-07 |
| 2023-03-31 | $2.27B 10-Q · filed 2023-05-08 |
| 2022-12-31 | $2.32B 10-K · filed 2023-02-27 |
| 2022-09-30 | $2.28B 10-Q · filed 2022-11-07 |
| 2022-06-30 | $2.34B 10-Q · filed 2022-08-08 |
| 2022-03-31 | $2.39B 10-Q · filed 2022-05-09 |
| 2021-12-31 | $2.58B 10-K · filed 2022-02-28 |
| 2021-09-30 | $2.59B 10-Q · filed 2021-11-08 |
| 2021-06-30 | $2.62B 10-Q · filed 2021-08-09 |
| 2021-03-31 | $2.60B 10-Q · filed 2021-05-10 |
| 2020-12-31 | $2.65B 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |